{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:36:08Z","timestamp":1780576568894,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-RTF21nov-0008"],"award-info":[{"award-number":["MOH-RTF21nov-0008"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS108968-01"],"award-info":[{"award-number":["1R01NS108968-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41684-024-01460-w","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:03:35Z","timestamp":1731665015000},"page":"363-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Murine model of minimally invasive nasal depot (MIND) technique for central nervous system delivery of blood\u2013brain barrier-impermeant therapeutics"],"prefix":"10.1038","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-7764","authenticated-orcid":false,"given":"Andy J.","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-724X","authenticated-orcid":false,"given":"Valentina","family":"Di Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-671X","authenticated-orcid":false,"given":"Anisha","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-881X","authenticated-orcid":false,"given":"Mansoor","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Bleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"1460_CR1","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","volume":"8","author":"X Dong","year":"2018","unstructured":"Dong, X. Current strategies for brain drug delivery. Theranostics 8, 1481\u20131493 (2018).","journal-title":"Theranostics"},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge, W. M. The blood\u2013brain barrier: bottleneck in brain drug development. NeuroRx 2, 3\u201314 (2005).","journal-title":"NeuroRx"},{"key":"1460_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"M Agrawal","year":"2018","unstructured":"Agrawal, M. et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J. Control. Release 281, 139\u2013177 (2018).","journal-title":"J. Control. Release"},{"key":"1460_CR4","doi-asserted-by":"publisher","unstructured":"Lee, D. & Minko, T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13122049 (2021).","DOI":"10.3390\/pharmaceutics13122049"},{"key":"1460_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.wjorl.2015.09.001","volume":"1","author":"MM Miyake","year":"2015","unstructured":"Miyake, M. M. & Bleier, B. S. Bypassing the blood\u2013brain barrier using established skull base reconstruction techniques. World J. Otorhinolaryngol. Head Neck Surg. 1, 11\u201316 (2015).","journal-title":"World J. Otorhinolaryngol. Head Neck Surg."},{"key":"1460_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2021.01.027","volume":"331","author":"S Padmakumar","year":"2021","unstructured":"Padmakumar, S. et al. Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J. Control. Release 331, 176\u2013186 (2021).","journal-title":"J. Control. Release"},{"key":"1460_CR7","doi-asserted-by":"publisher","first-page":"120989","DOI":"10.1016\/j.biomaterials.2021.120989","volume":"276","author":"S Padmakumar","year":"2021","unstructured":"Padmakumar, S. et al. Osmotic core\u2013shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach. Biomaterials 276, 120989 (2021).","journal-title":"Biomaterials"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"114696","DOI":"10.1016\/j.expneurol.2024.114696","volume":"374","author":"DS AA","year":"2024","unstructured":"AA, D. S., Kulkarni, P., Ferris, C. F., Amiji, M. M. & Bleier, B. S. Mild repetitive TBI reduces brain-derived neurotrophic factor (BDNF) in the substantia nigra and hippocampus: a preclinical model for testing BDNF-targeted therapeutics. Exp. Neurol. 374, 114696 (2024).","journal-title":"Exp. Neurol."},{"key":"1460_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jconrel.2024.06.056","volume":"372","author":"V Di Francesco","year":"2024","unstructured":"Di Francesco, V. et al. Minimally invasive nasal infusion (MINI) approach for CNS delivery of protein therapeutics: a case study with ovalbumin. J. Control. Release 372, 674\u2013681 (2024).","journal-title":"J. Control. Release"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"e0208122","DOI":"10.1371\/journal.pone.0208122","volume":"13","author":"GN Pawar","year":"2018","unstructured":"Pawar, G. N., Parayath, N. N., Nocera, A. L., Bleier, B. S. & Amiji, M. M. Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting. PLoS ONE 13, e0208122 (2018).","journal-title":"PLoS ONE"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"660841","DOI":"10.3389\/fphar.2021.660841","volume":"12","author":"G Pawar","year":"2021","unstructured":"Pawar, G. et al. Endonasal CNS delivery system for blood\u2013brain barrier impermeant therapeutic oligonucleotides using heterotopic mucosal engrafting. Front. Pharmacol. 12, 660841 (2021).","journal-title":"Front. Pharmacol."},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms21031170","volume":"21","author":"E Palasz","year":"2020","unstructured":"Palasz, E. et al. BDNF as a promising therapeutic agent in Parkinson\u2019s disease. Int. J. Mol. Sci. 21, 1170 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1460_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/ph17081070","volume":"17","author":"AK Madadi","year":"2024","unstructured":"Madadi, A. K. & Sohn, M. J. Advances in intrathecal nanoparticle delivery: targeting the blood-cerebrospinal fluid barrier for enhanced CNS drug delivery. Pharmaceuticals 17, 1070 (2024).","journal-title":"Pharmaceuticals"},{"key":"1460_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jconrel.2024.05.018","volume":"370","author":"LM Arms","year":"2024","unstructured":"Arms, L. M. et al. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma. J. Control. Release 370, 835\u2013865 (2024).","journal-title":"J. Control. Release"},{"key":"1460_CR15","doi-asserted-by":"publisher","first-page":"131491","DOI":"10.1016\/j.ijbiomac.2024.131491","volume":"267","author":"DG Gadhave","year":"2024","unstructured":"Gadhave, D. G. et al. Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine\u2014development & characterization in physiologically relevant 3D tissue models. Int. J. Biol. Macromol. 267, 131491 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"1460_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2022.11.051","volume":"353","author":"X Gao","year":"2023","unstructured":"Gao, X. et al. Mucus adhesion vs. mucus penetration? Screening nanomaterials for nasal inhalation by MD simulation. J. Control. Release 353, 366\u2013379 (2023).","journal-title":"J. Control. Release"},{"key":"1460_CR17","doi-asserted-by":"publisher","first-page":"134385","DOI":"10.1016\/j.ijbiomac.2024.134385","volume":"277","author":"A Lofts","year":"2024","unstructured":"Lofts, A. et al. In situ-gelling hydrophobized starch nanoparticle-based nanoparticle network hydrogels for the effective delivery of intranasal olanzapine to treat brain disorders. Int. J. Biol. Macromol. 277, 134385 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe, L. et al. Advances and challenges of liposome assisted drug delivery. Front. Pharmacol. 6, 286 (2015).","journal-title":"Front. Pharmacol."}],"container-title":["Lab Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01460-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:05:45Z","timestamp":1732626345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41684-024-01460-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1038\/s41684-024-01460-w","relation":{},"ISSN":["0093-7355","1548-4475"],"issn-type":[{"value":"0093-7355","type":"print"},{"value":"1548-4475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.C. received consulting fees from Acclarent Inc, MicrogenDx, and Elsevier Inc. B.S.B. holds a patent assigned to Massachusetts Eye and Ear covering transmucosal delivery methods to the CNS. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}